ctDNA in Metastatic Settings to Assess Progression & Molecular Responses for the Identification of High-Risk Patients

Time: 12:00 pm
day: Day Two


  • How ctDNA is used for progression and identifying high risk patients that will progress further than others in the metastatic setting?
  • How to implement ctDNA surrogate biomarkers in clinical trials?
  • What is the best assay to assess the molecular response in metastatic setting?
  • How to harmonize the generation of data across the industry to do meta-data analysis for on-going clinical trials and learn how to use ctDNA?